Metoprolol is a selective beta-1 blocker commonly employed as the succinate and tartrate derivatives depending if the formulation is designed to be of immediate release or extended release. The possibility of the generation of these formulations comes from the lower systemic bioavailability of the succinate derivative. To this date, it is one of the preferre...
Metoprolol is indicated for the treatment of angina, heart failure, myocardial infarction, atrial fibrillation, atrial flutter and hypertension.
Some off-label uses of metoprolol include supraventricular tachycardia and thyroid storm.
...
1307.19.1 Boehringer Ingelheim Investigational Site, Biberach, Germany
Creighton University, Omaha, Nebraska, United States
VU University Medical Center, Amsterdam, Netherlands
Antonius Ziekenhuis, Sneek, Netherlands
University Medical Center Groningen, Groningen, Netherlands
Hopital du Sacre-Coeur de Montreal, Montreal, Quebec, Canada
St. Boniface General, Winnipeg, Manitoba, Canada
Ajou University School of Medicine, Suwon, Gyeonggi, Korea, Republic of
Charleston Area Medical Center, Charleston, West Virginia, United States
Xijing Hospital, Department of Cardiology, Xi'an, China
Maimonides Medical Center, Brooklyn, New York, United States
State Research Institute of Circulation Pathology, Novosibirsk, Russian Federation
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.